Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-09-25

Clinical Trial Update: Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066 [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing the effect of carbohydrate in diet and supplements on GI tolerability of LIK066 in obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LIK066 (LIK066)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Obesity | Phase 2 | Status: COMPLETED | Results posted: 2018-09-25